- Home
- FLX vs CRGX Comparison
FLX vs CRGX Comparison
Compare FLX & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- CRGX
- Stock Information
- Founded
- FLX 2013
- CRGX 2021
- Country
- FLX China
- CRGX United States
- Employees
- FLX N/A
- CRGX N/A
- Industry
- FLX
- CRGX
- Sector
- FLX
- CRGX
- Exchange
- FLX NYSE
- CRGX Nasdaq
- Market Cap
- FLX 603.7M
- CRGX 621.4M
- IPO Year
- FLX 2024
- CRGX 2023
- Fundamental
- Price
- FLX $7.95
- CRGX $12.39
- Analyst Decision
- FLX
- CRGX Strong Buy
- Analyst Count
- FLX 0
- CRGX 6
- Target Price
- FLX N/A
- CRGX $31.80
- AVG Volume (30 Days)
- FLX 15.7K
- CRGX 287.3K
- Earning Date
- FLX 02-27-2025
- CRGX 11-12-2024
- Dividend Yield
- FLX N/A
- CRGX N/A
- EPS Growth
- FLX N/A
- CRGX N/A
- EPS
- FLX 0.19
- CRGX N/A
- Revenue
- FLX $663,142,775.00
- CRGX N/A
- Revenue This Year
- FLX N/A
- CRGX N/A
- Revenue Next Year
- FLX N/A
- CRGX N/A
- P/E Ratio
- FLX $40.88
- CRGX N/A
- Revenue Growth
- FLX 1.31
- CRGX N/A
- 52 Week Low
- FLX $6.50
- CRGX $10.91
- 52 Week High
- FLX $21.95
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- CRGX 39.66
- Support Level
- FLX N/A
- CRGX $10.91
- Resistance Level
- FLX N/A
- CRGX $15.75
- Average True Range (ATR)
- FLX 0.00
- CRGX 1.20
- MACD
- FLX 0.00
- CRGX -0.11
- Stochastic Oscillator
- FLX 0.00
- CRGX 30.08
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.